Skip to main content
BioAdvance NewsInnervacePortfolio News

Innervace Secures Up to $40 Million to Advance Novel Regenerative Medicine Platform for Neurological Disorders

By September 8, 2022November 1st, 2024No Comments

Innervace Secures Up to $40 Million to Advance Novel Regenerative Medicine Platform for Neurological Disorders

Series A financing round, led by Deerfield Management, to accelerate a new cell therapy modality for the treatment of neurological disorders, including Parkinson’s Disease

See more here